Retatrutide COA & Certificate of Analysis

A Certificate of Analysis (COA) is a formal document issued by the manufacturer that records the analytical test results for a specific production batch. For Retatrutide, the COA confirms that the batch has been tested and meets the agreed quality specification before shipment.

The COA is batch-specific: every field refers to the actual production batch being shipped, not a generic or representative result. Each COA carries a unique batch or lot number that links it to the corresponding production and testing records.

For B2B OEM partners, the COA is a standard contractual deliverable. It provides the analytical basis for acceptance of the material and supports the partner's own quality management and regulatory documentation requirements.

Peptide content testing — also referred to as assay — determines the actual quantity of Retatrutide present in a batch, expressed as a percentage of the labelled amount or as an absolute mass per unit. This test is distinct from HPLC purity: purity measures the proportion of the target compound relative to impurities, while content testing measures the absolute amount of peptide present.

For lyophilised Retatrutide, peptide content is typically determined by UV absorbance or amino acid analysis. The result is reported on the COA and is used by OEM partners to calculate accurate dosing for formulation development.

Content testing is particularly relevant for partners who are developing injectable formulations or fill-finish operations, where the precise peptide mass per vial must be confirmed against the formulation specification.

Residual water content in lyophilised Retatrutide is measured by Karl Fischer titration, the standard method for quantitative water determination in pharmaceutical materials. The result is expressed as a percentage by weight.

Water content is a critical quality parameter for lyophilised peptides: elevated moisture accelerates chemical degradation, including oxidation and deamidation, and reduces shelf-life. The COA reports the water content result against the agreed specification, allowing partners to assess the batch condition at the time of manufacture.

For long-term storage and cold-chain shipment, water content data from the COA provides a baseline reference point. Partners who perform re-testing on receipt can compare their result against the manufacturer COA value to assess any change during transit.

Bacterial endotoxin testing is performed on Retatrutide batches supplied for injectable formulation use. The test detects the presence of lipopolysaccharide (LPS) endotoxins derived from gram-negative bacteria, which can cause pyrogenic reactions if present above threshold levels in injectable preparations.

The standard method is the Limulus Amebocyte Lysate (LAL) test, which is sensitive to endotoxin concentrations in the EU/mg or EU/mL range. The result is reported on the COA against the agreed specification limit.

Endotoxin testing is not required for all Retatrutide applications — it is relevant primarily for partners developing injectable formulations or conducting in vivo studies. Partners should specify their endotoxin requirement at the time of ordering so that the appropriate testing can be included in the batch release protocol.

Every Retatrutide batch produced by ShiLai™ Healthcare is assigned a unique batch or lot number at the point of manufacture. This number appears on the COA, the product label, and the shipment documentation, providing a consistent identifier that links all documents for a given production run.

The batch number enables full traceability from the COA back through the batch release records to the synthesis and formulation documentation. For OEM partners who require traceability as part of their quality management system, the batch number is the primary reference for any post-receipt query or investigation.

Batch-specific documentation — including the COA, HPLC chromatogram, and LC-MS spectrum — is retained by ShiLai™ Healthcare and can be re-issued on request. Partners who require extended documentation retention periods should specify this requirement in the supply agreement.

A manufacturer COA and a third-party laboratory test report serve different documentation roles and are not interchangeable.

The manufacturer COA is issued by ShiLai™ Healthcare at the point of batch release. It documents the analytical results for the full production batch as manufactured — including purity, identity, appearance, and batch identification — and accompanies the batch from manufacture to shipment.

A third-party test report, such as a Janoshik test, is produced by an independent laboratory from a sample submitted after manufacture. It provides buyer-initiated verification of the sample condition at the time of testing, independent of the manufacturer's documentation.

Both documents can be relevant in B2B procurement: the COA establishes the manufacturer's release specification for the batch; a third-party test provides independent verification of a specific sample submitted by the buyer.